Related Experiment Video
Updated: Aug 19, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid-lowering interventions in managed care settings
Insights
Improving lipid management is crucial for preventing coronary heart disease (CHD). Quality improvement programs and physician education can enhance lipid-lowering therapy effectiveness and reduce healthcare costs.
Area of Science:
- Cardiology
- Public Health
- Health Services Research
Background:
- Elevated serum lipid levels strongly correlate with coronary heart disease (CHD).
- Current screening, treatment, and follow-up for hyperlipidemia are often inadequate in managed care settings.
- Suboptimal utilization of lipid-lowering therapy limits primary and secondary prevention of CHD.
Purpose of the Study:
- To evaluate the effectiveness of a quality improvement program for hyperlipidemia management.
- To identify strategies for enhancing the efficacy and cost-effectiveness of lipid-lowering therapies.
- To reduce CHD-related morbidity, mortality, and economic burden.
Main Methods:
- A three-phase hyperlipidemia outcomes management program conducted at 27 US managed care organizations (MCOs).
- Implementation of physician education and integrated quality improvement initiatives.
- Individualized drug selection and dosage adjustments to meet National Cholesterol Education Program goals.
Main Results:
- Findings from the initial phase confirmed suboptimal hyperlipidemia management practices.
- Physician education and quality improvement programs demonstrated potential to enhance lipid-lowering therapy efficacy.
- Individualized treatment strategies can improve cost-effectiveness by optimizing drug acquisition costs.
Conclusions:
- Comprehensive quality improvement programs can significantly improve hyperlipidemia management.
- Enhanced physician education and tailored therapeutic approaches are key to optimizing lipid-lowering therapy.
- These interventions hold the potential to decrease CHD-related health issues and associated economic costs.
Abstract:
Effective screening, treatment, and follow-up of patients with elevated serum lipid levels is important because of the very strong association between this condition and coronary heart disease (CHD). Screening of patients with and without CHD for hyperlipidemia is not generally carried out properly by managed care organizations (MCOs) or in other settings. Primary and secondary prevention are inadequate in most patients with this condition; even in patients who are treated, lipid-lowering therapy is often not used to its full potential. These trends have been confirmed by findings in the first of a three-phase hyperlipidemia outcomes management program carried out at 27 US MCOs. The efficacy of lipid-lowering therapy can be enhanced by physician education and comprehensive, integrated quality improvement programs. The cost-effectiveness of such treatment can be improved by individualizing both drug and dose to achieve National Cholesterol Education Program goals at the lowest drug acquisition cost. The quality improvement program described and others like it have the potential to reduce the morbidity and mortality associated with CHD while decreasing the huge economic burden associated with this disease. Several such programs have been undertaken at MCOs, some with more success than others. Interventions and assessments of the type planned in phases 2 and 3 of this program can help to reduce the cost of lipid-lowering therapy without compromising cholesterol goal achievement.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:26Angina IV: Management
01:26Atherosclerosis III: Management
01:23Atherosclerosis IV: Nursing Management
01:27Peripheral Artery Disease III: Interprofessional Care